zalcitabine has been researched along with 3'-azido-2',3'-dideoxyadenosine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, M; Balzarini, J; Broder, S; De Clercq, E; Herdewijn, P; Pauwels, R; Vanderhaeghe, H | 1 |
| Amblard, F; Bassit, L; Bondada, L; Coats, SJ; Detorio, M; Grier, J; Hernandez-Santiago, BI; Koontz, D; Mellors, JW; Rapp, KL; Schinazi, RF; Sluis-Cremer, N | 1 |
| Asif, G; Coats, SJ; Detorio, M; Koontz, D; Mellors, JW; Meteer, JD; Schinazi, RF; Sluis-Cremer, N; Solomon, S; Zhang, HW | 1 |
3 other study(ies) available for zalcitabine and 3'-azido-2',3'-dideoxyadenosine
| Article | Year |
|---|---|
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
Topics: Antiviral Agents; Cell Line; Chemical Phenomena; Chemistry; Cytopathogenic Effect, Viral; Deoxyribonucleosides; HIV; Humans; Structure-Activity Relationship; T-Lymphocytes; Virus Replication | 1987 |
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Molecular Structure; Reverse Transcriptase Inhibitors | 2009 |
The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Azides; Base Sequence; Dideoxyadenosine; Dideoxynucleosides; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Mutagenesis, Site-Directed; Reverse Transcriptase Inhibitors; Sequence Analysis, RNA; Zalcitabine; Zidovudine | 2011 |